May 6th 2025
The bispecific T-cell engager tarlatamab demonstrated favorable antitumor activity in a small cohort with small cell lung cancer (SCLC), but it was also linked to higher rates of serious adverse events like cytokine release syndrome than seen in clinical trials.
Watch the series now!
Chronic Conditions May Be Barrier to Timely Cervical Cancer Screening
ICU Admission Reduces Survival, Augments Costs Among Patients With AML
Addressing the Psychosocial Needs in Older Breast Cancer Patients
Combining IORT With Chemotherapy Improves Survival in Pancreatic Cancer